Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study
Pfizer’s abrocitinib demonstrates significant skin clearance in atopic dermatitis trial. Credit: Lauri Silvennoinen.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
